• Who We Are
    • Letter from the CEO
    • About Us
    • Our Team
  • Science
  • Pipeline
    • Pipeline Overview
    • NVD-003
    • NVD-X3
  • Patients
  • Investors
  • Contact
  • Careers
What's New
  • Home
  • Who We Are
    • Letter from the CEO
    • About Us
    • Our Team
  • Science
  • Pipeline
    • Pipeline Overview
    • NVD-003
    • NVD-X3
  • Patients
  • Investors
  • What’s New
  • Contact
  • Careers

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

by Novadip | Oct 28, 2021 | Press Releases

New investment to fuel continued growth of 3M³ platform for the development of products in tissue reconstruction and oncology Mont Saint-Guibert, Belgium – October 28, 2021 – Novadip Biosciences (“Novadip” or “the Company”), a clinical stage company developing...

Novadip raises $22M in series B funding for US trial of bone regeneration therapy

by Novadip | Oct 18, 2021 | Featured News

Novadip SA raised €19 million (US$22.1 million) in a first close of a series B round to progress its autologous bone regeneration therapy, NVD-003, on either side of the Atlantic. The company is also working on an allogeneic regenerative approach, which is still...

Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion

by Novadip | Jun 15, 2021 | Press Releases

Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion.  Primary endpoint met, study validates autologous cell therapy 3M³ platform for bone regeneration and demonstrates manufacturing capabilitiesNext generation autologous...

IND approval from the FDA for regenerative bone product NVD-003

by Novadip | Mar 4, 2021 | Press Releases

Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003 Authorization to start clinical trial in the US granted for rare paediatric bone disease Mont-Saint-Guibert, Mar 4, 2021 (GlobeNewswire) – Novadip Biosciences (“Novadip”), a...

23 décembre 2020 – Visite de Willy Borsus, Ministre de l’Economie, du Commerce extérieur, de la Recherche et de l’Innovation

by Novadip | Dec 23, 2020 | Press Releases

Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation – Dual designations granted for NVD-003 for the Treatment of Congenital Pseudarthrosis of the Tibia a serious and debilitating condition that primarily affects children...
« Older Entries
Next Entries »

Stay Updated by Joining Our Email List

Success!

Subscribe

NOVADIP

Novadip is advancing the standard of care
in bone and tissue regenerative medicine

info@novadip.com

+32 (10) 779 220

Navigation

Who We Are

Our Science

Our Pipeline

Patients

Investors

What’s New

Get In Touch

Contact

Careers

Legal

Privacy Policy

Cookie Policy

Information Notice

Proposed Expanded Access Policy

©2022 NOVADIP. All Rights Reserved.

  • Follow